

Vertical

Home Health & Hospice

Focus

Q1 2022 Acquisition Activity and Outlook

Home Health and Hospice Activity Dips After Busy 2021; Expect a Bounce Back Next Three Quarters

The first quarter of 2022 delivered twenty-eight reported home health and hospice acquisitions, coming down from peaks levels to end the past year. However, Q1 has historically brought lower M&A levels, and we expect deal volume to rebound throughout the year.

In January, Agape Care Group, a portfolio company of Ridgemont Equity Partners announced the acquisition of Lanier Hospice based in Buford, Georgia. The company now covers 65% of Georgia and all counties of South Carolina, caring for 2,100 patients between the two states. In February, Addus HomeCare announced the acquisition of JourneyCare, a provider of hospice care serving the greater Chicago area for a cash purchase price of approximately \$85 million. JourneyCare serves an average daily census of approximately 750 patients in thirteen county territory. Also in February, HouseWorks, an independent home care company, announced its agreement to acquire Greater Boston Home Health Care, a leading home care provider serving Medicaid, dual-eligible and private pay clients throughout Eastern Massachusetts. HouseWorks is a leader in home care serving Greater Boston, Philadelphia, New Hampshire, and Southern Maine.

Eric J. Yetter

Managing Director and
Healthcare Team Leader

(615) 477-4741

eric.yetter@focusbankers.com

J. Andrew Snyder


Managing Director

(615) 319-3233


andy.snyder@focusbankers.com

We expect heavy M&A activity to pick back up throughout 2022 as platforms seek build their networks before future recapitalizations.

12-Month Quarterly Acquisition Trend



PE Consolidation Lifecycle Positioning



Notable Deals in Q1 2022

Buyer	Target	State	Date
Agape Care Group	Lanier Hospice	GA	1/11/22
Addus HomeCare	JourneyCare Hospice	IL	2/2/22
Houseworks	Greater Boston Home Health Care	MA	2/20/22

Home Health & Hospice – Q1 2022 Acquisition Activity and Outlook

www.focusbankers.com

Legal Disclaimer/Other Disclosures

This report is for informational purposes only and does not constitute an offer, invitation, solicitation, or recommendation to buy, sell, subscribe for, or issue any securities and shall not form the basis of any contract with FOCUS Investment Banking, LLC. This report was prepared exclusively for the benefit and internal use of the person or company to whom it is directly addressed and delivered (including such recipient's subsidiaries, the "Company") in order to assist the Company in evaluating, on a preliminary basis, the feasibility of a possible transaction or transactions and does not carry any right of publication or disclosure, in whole or in part, to any other party. This report is for discussion purposes only and is incomplete without reference to, and should be viewed solely in conjunction with, the oral briefing provided by FOCUS Investment Banking, LLC ("FOCUS"). Neither this report nor any of its contents may be used for any other purpose without the prior written consent of FOCUS.

The information in this report is based upon FOCUS estimates and reflects prevailing conditions and our views as of this date, all of which are accordingly subject to change. In preparing this report, we have relied upon and assumed, without independent verification, the accuracy and completeness of information available from public sources. In addition, our analyses are not and do not purport to be appraisals of the assets, stock, or business of the Company or any other entity. FOCUS makes no representations as to the actual value which may be received in connection with a transaction or the legal, tax or accounting effects of consummating a transaction. FOCUS does not render legal or tax advice, and the information contained in this communication should not be regarded as such. The information in this report does not take into account the effects of a possible transaction (or transactions) involving an actual or potential change of control, which may have significant valuation and other effects. The information in this report is confidential.

If you are not the intended recipient or an authorized representative of the intended recipient, you are hereby notified that any review, dissemination or copying of this report is prohibited.

Copyright Notice

The contents of this paper, including (but not limited to) all written material, images, analysis, and graphics, are protected under international copyright and trademark laws. You may not copy, publish, reproduce, broadcast, modify, reprint, transmit or distribute any material from this paper or pdf in whole or in part without the express written permission of FOCUS.